ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022

NEW YORK, April 15, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of AbbVie Inc. (NYSE: ABBV).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/abbvie-inc-loss-submission-form/?id=25976&from=4

The lawsuit seeks to recover losses for shareholders who purchased AbbVie between April 30, 2021 and August 31, 2021.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until June 6, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, AbbVie Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE Jakubowitz Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED